{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-221120","form_type":"8-K","ticker":null,"cik":"0001560241","company_name":"G1 Therapeutics, Inc.","filed_at":"2024-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.512476+00:00","generated_at":"2026-05-31T03:57:18.220348+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Pharmacosmos completes acquisition of G1 Therapeutics for $405M; shares delisted","bullets":["Tender offer expired with 39,486,447 shares (74.64%) tendered; all conditions satisfied.","G1 stockholders receive $7.15/share cash; total equity value ~$405M.","Shares delisted from Nasdaq; G1 becomes indirect wholly owned subsidiary of Pharmacosmos.","Board and officers replaced; Josh Franklin named CEO of surviving corporation.","Loan agreement with Hercules Capital repaid in full and terminated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-221120","json":"https://secwatch.observer/filing/0001193125-24-221120.json","markdown":"https://secwatch.observer/filing/0001193125-24-221120.md","text":"https://secwatch.observer/filing/0001193125-24-221120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/d823642d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:57:18.220348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"054d058c33","claim":"John E. Bailey, Jr. departed as other_named_officer at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Mark Avagliano, Rajesh K. Malik, M.D., Terry L. Murdock, and John W. Umstead V ceased serving as an officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"0ec3877a07","claim":"John E. Bailey, Jr. resigned as director at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Cynthia L. Flowers, Jacks Lee, Glenn P. Muir, Garry A. Nicholson, Alicia Secor and Norman E. Sharpless, M.D. resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"278cbeb8e4","claim":"Jacks Lee resigned as director at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Cynthia L. Flowers, Jacks Lee, Glenn P. Muir, Garry A. Nicholson, Alicia Secor and Norman E. Sharpless, M.D. resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"3f08ab718f","claim":"Cynthia L. Flowers resigned as director at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Cynthia L. Flowers, Jacks Lee, Glenn P. Muir, Garry A. Nicholson, Alicia Secor and Norman E. Sharpless, M.D. resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"434b41ad3b","claim":"Mark Avagliano departed as other_named_officer at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Mark Avagliano, Rajesh K. Malik, M.D., Terry L. Murdock, and John W. Umstead V ceased serving as an officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"55932d4916","claim":"Josh Franklin was appointed as director at G1 Therapeutics, Inc..","evidence_excerpt":"the director of Purchaser, Josh Franklin, became the director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"72c81a200e","claim":"John W. Umstead V departed as other_named_officer at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Mark Avagliano, Rajesh K. Malik, M.D., Terry L. Murdock, and John W. Umstead V ceased serving as an officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"790042e48d","claim":"Rajesh K. Malik, M.D. departed as other_named_officer at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Mark Avagliano, Rajesh K. Malik, M.D., Terry L. Murdock, and John W. Umstead V ceased serving as an officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"80a0b9977e","claim":"Terry L. Murdock departed as other_named_officer at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Mark Avagliano, Rajesh K. Malik, M.D., Terry L. Murdock, and John W. Umstead V ceased serving as an officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"879e9ebb33","claim":"Alicia Secor resigned as director at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Cynthia L. Flowers, Jacks Lee, Glenn P. Muir, Garry A. Nicholson, Alicia Secor and Norman E. Sharpless, M.D. resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"a211bd08e0","claim":"Norman E. Sharpless, M.D. resigned as director at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Cynthia L. Flowers, Jacks Lee, Glenn P. Muir, Garry A. Nicholson, Alicia Secor and Norman E. Sharpless, M.D. resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"a70f5cff3f","claim":"Josh Franklin was appointed as Chief Executive Officer and President at G1 Therapeutics, Inc..","evidence_excerpt":"Mr. Franklin, as Chief Executive Officer and President of Purchaser immediately prior to the Effective Time, became the Chief Executive Officer and President of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"aa8d40ed6d","claim":"Garry A. Nicholson resigned as director at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Cynthia L. Flowers, Jacks Lee, Glenn P. Muir, Garry A. Nicholson, Alicia Secor and Norman E. Sharpless, M.D. resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"f56a60fbeb","claim":"Glenn P. Muir resigned as director at G1 Therapeutics, Inc..","evidence_excerpt":"each of John E. Bailey, Jr., Cynthia L. Flowers, Jacks Lee, Glenn P. Muir, Garry A. Nicholson, Alicia Secor and Norman E. Sharpless, M.D. resigned as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"d22ac3a3b27cd0170c2d958a369baef8fca41eef","claim":"G1 Therapeutics, Inc. underwent a change of control involving Pharmacosmos A/S for $7.15 per share (closed 2024-09-18).","evidence_excerpt":"“Offer”) to purchase all of the issued and outstanding shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at a price of $7.15 per Share, net to the seller in cash, without interest and subject to any applicable withholding of taxes (the “Offer Price”). The Offer and related withdrawal rights expired at","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Pharmacosmos A/S"},{"label":"Consideration","value":"$7.15 per share"},{"label":"Closing","value":"2024-09-18"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}